Divi's Laboratories shares hit record high rising 84% YTD; buy, sell or hold after Q2 results 2026? Brokerages report
LiveMint

Divi's Laboratories shares reached a record high following strong Q2 financial results and positive broker updates.
Divi's Laboratories shares surged to a fresh 52-week high, bringing year-to-date gains to 84% following strong Q2 FY27 results. The company reported a 64% year-on-year increase in net profit to ₹1,127 crore, along with a 35% growth in revenue to ₹3,676 crore. Brokerages highlighted strong growth potential in areas such as custom synthesis and peptides, boosting investor confidence.
Why it matters: The company's strong Q2 performance and favorable brokerage outlook highlight robust growth in custom synthesis and peptides, driving significant stock appreciation.



